Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Professor of Medicine
Stanford University
Stanford, CA

Topics of Professional Interest:
  • Antiretroviral therapy
  • HIV and AIDS in Africa
  • Mother-to-child transmission of HIV
  • HIV resistance
  • Global AIDS
  • Drug resistance
  • HIV pathogenesis
  • Treatment access and strategies
Current Professional Summary:

Dr Katzenstein is a Professor of Medicine in the Division of Infectious Diseases at Stanford University, and Associate Medical Director of the Stanford University AIDS Clinical Trials Group. He is also Director of the Center for AIDS Research Laboratory at Stanford. He is currently directing antiretroviral treatment and drug resistance studies in Africa and Asia. Many of the studies he led abroad have been collaborations between clinicians, microbiologists, and immunologists to identify new diagnostics for HIV and opportunistic infections. His experiences in laboratory and clinical studies are well suited to the validation of PCR diagnostics for tuberculosis in the treatment of HIV-infected individuals.

Committees and Organizations:
  • Member, Antiretroviral Therapy Guidelines Panel, IAS–USA (1995-2006)
  • ACTG Pharmacology RAC
  • HIVresistance.com
  • AIDSETI
  • Stanford-Berkeley African Studies Committee
  • Member, AIDS Clinical Epidemiology Study Section Charter (2008)
  • Chair, Southern African Treatment Resistance Network (2006)
  • Chair, Biologic Outcome Working Group, NIMH C-pol study (2000-2008)
  • Chair, HIV Resistance Web Board of Scientific Advisors (1999-2003)
  • Member, HIV Disease Research Agenda Committee, ACTG (1995-2000)
  • Member, University of California University Wide Task Force on AIDS
Honors and Awards:
  • Doris Duke Distinguished Clinical Research Scientist
Education:
  • University of California San Diego, BA (1973)
  • University of California San Diego, MD (1977)
  • University of California San Diego, Fellowship, Internal Medicine (1980)
  • University of California Davis, Fellowship, Infectious Diseases (1983)
Selected Publications:
  1. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES; AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009 Dec 3;361(23):2230-2240.
  2. Kassaye S, Johnston E, McColgan B, Kantor R, Zijenah L, Katzenstein D. Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):9-18.
  3. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med. 2008 Sep 22;168(17):1910-1918.
  4. Tebas P, Henry WK, Matining R, Weng-Cherng D, Schmitz J, Valdez H, Jahed N, Myers L, Powderly WG, Katzenstein D. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS One. 2008 Apr 23;3(4):e2021.
  5. Kassaye S, Lee E, Kantor R, Johnston E, Winters M, Zijenah L, Mateta P, Katzenstein D. Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis. AIDS Res Hum Retroviruses. 2007 Aug;23(8):1055-1061.
  6. Zijenah LS, Kadzirange G, Rusakaniko S, Kufa T, Gonah N, Tobaiwa O, Gwanzura C, Matsikire E, Katzenstein DA. A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe. Cent Afr J Med. 2006 Jan-Feb;52(1-2):1-8.
  7. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, Shafer RW. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005 Apr;2(4):e112.
  8. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004 Jul 14;292(2):251-265.
  9. Louie LG, Hartogensis WE, Jackman RP, Schultz KA, Zijenah LS, Yiu CH, Nguyen VD, Sohsman MY, Katzenstein DK, Mason PR. Mycobacterium tuberculosis/HIV-1 coinfection and disease: role of human leukocyte antigen variation. J Infect Dis. 2004 Mar 15;189(6):1084-1090.
  10. Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, Albrecht MA; ACTG 364 Study Team. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS. 2003 Apr 11;17(6):821-830.